GlaxoSmithKline may be onto something big:
GlaxoSmithKline Plc’s drug Tykerb, in an unexpected finding, cut the number of breast cancer stem cells by half in 30 patients, and two-thirds were cancer free after follow-up treatment with other therapies.
The finding, reported today at the San Antonio Breast Cancer Symposium in Texas, supports the newest theory in cancer, that a tiny number of stem cells lurking within tumors are the driving force that fuels their growth. Researchers from Baylor College of Medicine in Houston said the finding may be a first step toward changing the way cancer is treated.
Excellent news. There is, however, still no cure for modern Republicanism.